A drug dosage table is a useful tool to facilitate prescriptions of antiretroviral drugs for children in Thailand

International Journal of STD and AIDS

Volumn 16, Issue 6, 2005, Pages 420-426

  Ponnet, M ^a   Frederix, K ^a   Petdachai, W ^b   Wilson, D ^a   Eksaengsri, A ^c   Zachariah, Rony ^d  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Prachomklao Hospital   (Thailand)

^c Thailand Government Pharmaceutical Organization   (Thailand)

^d MÉDECINS SANS FRONTIÈRES   (Belgium)

Author keywords

Drug dosages; HAART; Paediatric formulations; Thailand

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIR; BIOZOLE; COTRIMOXAZOLE; DIDANOSINE; DIVIR; EFAVIRENZ; FLUCONAZOLE; GPO VIR; INDINAVIR; LAMIVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NELFINAVIR; NERAVIR; NEVIRAPINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ZILARVIR;

ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DOSE CALCULATION; DROWSINESS; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPPORTUNISTIC INFECTION; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RASH; SCHOOL CHILD; STANDARD; THAILAND;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; HIV INFECTIONS; HUMANS; PRESCRIPTIONS, DRUG; THAILAND;

EID: 20944440691     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462054094114     Document Type: Article

References (17)

1. UNAIDS. Report on the Global HIV/AIDS Epidemic. 1211 Geneva 27, Switzerland: UNAIDS, 2002 [www.unaids.org]
2. World Health Organization. Scaling Up Anti-Retroviral Therapy in Resource-Limited Settings. Guidelines for a Public Health Approach. Geneva: WHO QV268.5, June 2002
3. PENTA (Paediatric European Network for Treatment of AIDS). Guidelines for the Use of Antiretroviral Therapy in Paediatric HIV Infection 2003
4. United States Department of Health and Human Services. American Pediatric Guidelines 2003 [www.aidsinfo.nih.gov/ guidelines/pediatric/PED_062503.org]
5. National Guidelines for the Clinical Management of HIV Infection in Children and Adult. 7th edn. Thailand: Ministry of Public Health, 2002
6. Practical Guideline for Health Service System Development and Monitoring of ART in HIV+ Children: ARV drug dosage table page 32. Nonthaburi, Thailand: Ministry of Public Health, November 2002
7. Growth Charts 1999. Tiwanond Road, Muang District, Nonthaburi 11000, Thailand: Health Department, Ministry of Public Health
8. Behrman R, Klegman R, Arvin AM, eds., Nelson WE, senior ed. Nelson Textbook of Pediatrics. 17th edn. Philadelphia: Saunders, 2003
9. Ghosn J, Lamotte C, Ait-Mohand H, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/ 400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-14
10. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P. Safety and pharmacokinetics of once daily regimens of soft-gelcapsule Saquinavir plus Minidose Ritinovir in HIV-negative adults. Antimicrob Agents Chemother 2000;44: 2672-8
11. van Rossum MC, Fraaij LAP, Ronald de Groot. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002;2:93-102
12. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996;174: 713-21
13. Hainaut M, Peltier CA, Gerard M, Marissens D, Zissis G, Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr 2000;159:778-82
14. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 1999;13:1653-8
15. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000;9:1148-53
16. Goode M, McMaugh A, Crisp J, Wales S, Ziegler JB. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care 2003;15:403-8
17. Perez-Casas C, Berman D, Chirac P, et al. HIV/AIDS Medicines Pricing Report. Setting Objectives: Is There a Political Will? Geneva: MSF, 2000. Available at [www.accessmed-msf.org]